Recent Advances in Extracellular Vesicle-Based Therapies Using Induced Pluripotent Stem Cell-Derived Mesenchymal Stromal Cells.
Giuliana Minani BertolinoMarie MaumusChristian JorgensenDanièle NoëlPublished in: Biomedicines (2022)
Extracellular vesicles (EVs) are being widely investigated as acellular therapeutics in regenerative medicine applications. EVs isolated from mesenchymal stromal cells (MSCs) are by far the most frequently used in preclinical models for diverse therapeutic applications, including inflammatory, degenerative, or acute diseases. Although they represent promising tools as cell-free therapeutic agents, one limitation to their use is related to the batch-to-batch unreliability that may arise from the heterogeneity between MSC donors. Isolating EVs from MSCs derived from induced pluripotent stem cells (iMSCs) might allow unlimited access to cells with a more stable phenotype and function. In the present review, we first present the latest findings regarding the functional aspects of EVs isolated from iMSCs and their interest in regenerative medicine for the treatment of various diseases. We will then discuss future directions for their translation to clinics with good manufacturing practice implementation.
Keyphrases
- cell free
- primary care
- induced pluripotent stem cells
- mesenchymal stem cells
- bone marrow
- healthcare
- induced apoptosis
- drug induced
- liver failure
- cell cycle arrest
- oxidative stress
- high glucose
- diabetic rats
- circulating tumor
- respiratory failure
- single cell
- cell therapy
- stem cells
- cell death
- cell proliferation
- intensive care unit
- endoplasmic reticulum stress
- hepatitis b virus
- kidney transplantation
- aortic dissection
- high resolution